

Idiopathic Pulmonary Fibrosis

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

Trial Status Completed	Trial Runs In 1 Countries	Trial Identifier NCT03115619 ML39259
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](#). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

Hoffmann-La Roche
Sponsor

Phase

NCT03115619 ML39259
Trial Identifiers

Eligibility Criteria:

Gender All	Age >= 18 Years	Healthy Volunteers No
----------------------	---------------------------	---------------------------------